Chong Kun Dang Pharmaceutical Corp. (185750.KS)
KRW 91600.0
(-0.76%)
KRW 91600.0
(-0.76%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 408.65 Billion KRW | -5.56% |
| 2022 | 432.73 Billion KRW | 7.9% |
| 2021 | 401.05 Billion KRW | 9.82% |
| 2020 | 365.2 Billion KRW | 10.77% |
| 2019 | 329.7 Billion KRW | 8.22% |
| 2018 | 304.66 Billion KRW | 8.08% |
| 2017 | 281.89 Billion KRW | 3.02% |
| 2016 | 273.63 Billion KRW | 7.95% |
| 2015 | 253.47 Billion KRW | 11.95% |
| 2014 | 226.41 Billion KRW | 485.15% |
| 2013 | 38.69 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 103.06 Billion KRW | -68.45% |
| 2024 Q1 | 326.69 Billion KRW | 180.54% |
| 2023 Q3 | -94.09 Billion KRW | 5.29% |
| 2023 Q4 | 116.45 Billion KRW | 223.77% |
| 2023 FY | 408.65 Billion KRW | -5.56% |
| 2023 Q1 | 103.98 Billion KRW | -16.03% |
| 2023 Q2 | -99.34 Billion KRW | -195.54% |
| 2022 Q3 | 101.04 Billion KRW | -6.11% |
| 2022 Q2 | 107.61 Billion KRW | 7.36% |
| 2022 Q1 | 100.24 Billion KRW | -16.01% |
| 2022 FY | 432.73 Billion KRW | 7.9% |
| 2022 Q4 | 123.83 Billion KRW | 22.55% |
| 2021 Q1 | 91.1 Billion KRW | -21.86% |
| 2021 Q2 | 98.13 Billion KRW | 7.71% |
| 2021 Q3 | 92.47 Billion KRW | -5.77% |
| 2021 Q4 | 119.34 Billion KRW | 29.06% |
| 2021 FY | 401.05 Billion KRW | 9.82% |
| 2020 Q1 | 78.19 Billion KRW | -14.52% |
| 2020 Q3 | 86.84 Billion KRW | 3.92% |
| 2020 Q4 | 116.58 Billion KRW | 34.25% |
| 2020 Q2 | 83.57 Billion KRW | 6.88% |
| 2020 FY | 365.2 Billion KRW | 10.77% |
| 2019 Q2 | 83.45 Billion KRW | 16.0% |
| 2019 FY | 329.7 Billion KRW | 8.22% |
| 2019 Q4 | 91.47 Billion KRW | 10.43% |
| 2019 Q3 | 82.83 Billion KRW | -0.74% |
| 2019 Q1 | 71.94 Billion KRW | -14.03% |
| 2018 Q3 | 75.77 Billion KRW | -3.56% |
| 2018 Q4 | 83.68 Billion KRW | 10.43% |
| 2018 FY | 304.66 Billion KRW | 8.08% |
| 2018 Q2 | 78.57 Billion KRW | 17.93% |
| 2018 Q1 | 66.62 Billion KRW | -15.63% |
| 2017 Q1 | 67.61 Billion KRW | 0.0% |
| 2017 FY | 281.89 Billion KRW | 3.02% |
| 2017 Q2 | 68.02 Billion KRW | 0.6% |
| 2017 Q3 | 67.27 Billion KRW | -1.1% |
| 2017 Q4 | 78.97 Billion KRW | 17.4% |
| 2016 Q1 | 73.68 Billion KRW | 9.81% |
| 2016 Q2 | 75.23 Billion KRW | 2.11% |
| 2016 Q3 | 63.19 Billion KRW | -16.01% |
| 2016 Q4 | - KRW | -100.0% |
| 2016 FY | 273.63 Billion KRW | 7.95% |
| 2015 FY | 253.47 Billion KRW | 11.95% |
| 2015 Q4 | 67.1 Billion KRW | 2.59% |
| 2015 Q3 | 65.41 Billion KRW | 2.01% |
| 2015 Q2 | 64.12 Billion KRW | 12.81% |
| 2015 Q1 | 56.84 Billion KRW | -12.6% |
| 2014 Q1 | 52.07 Billion KRW | 0.0% |
| 2014 FY | 226.41 Billion KRW | 485.15% |
| 2014 Q2 | 58.09 Billion KRW | 11.55% |
| 2014 Q3 | 51.2 Billion KRW | -11.85% |
| 2014 Q4 | 65.03 Billion KRW | 27.01% |
| 2013 FY | 38.69 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -764.81% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -37.137% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -46.767% |
| HANDOK Inc. | 153.76 Billion KRW | -165.761% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -490.428% |
| Yuhan Corporation | 489.94 Billion KRW | 16.591% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | -33.131% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -877.893% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 33.114% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -467.71% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -134.66% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -920.286% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -336.825% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -256.205% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -764.81% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -862.184% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -444.518% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -596.84% |
| JW Holdings Corporation | 301.25 Billion KRW | -35.65% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -56.6% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -71.05% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -220.089% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -498.229% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -521.517% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -133.616% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -764.81% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -64.038% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 27.082% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -71.05% |
| Yuhan Corporation | 489.94 Billion KRW | 16.591% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -111.013% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -488.261% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -629.326% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -71.05% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -223.322% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -245.692% |
| CKD Bio Corp. | 25.19 Billion KRW | -1521.926% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -84.08% |
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -147.501% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -515.285% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -220.089% |
| Chong Kun Dang Holdings Corp. | 350.71 Billion KRW | -16.521% |
| Boryung Corporation | 285.16 Billion KRW | -43.307% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -366.811% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -134.66% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1916.904% |